| Langue d'origine | English |
|---|---|
| Pages (de-à) | E302-E311 |
| Journal | CMAJ |
| Volume | 192 |
| Numéro de publication | 12 |
| DOI | |
| Statut de publication | Published - mars 23 2020 |
Note bibliographique
Funding Information:Competing interests: Theodore Wein reports receiving grants from Allergan, Boehringer Ingelheim and Bayer, and grants and consulting fees from Servier, Allergan and Ipsen; conducting accredited continuing medical education sessions for Servier; and receiving travel reimbursement from Servier. David Gladstone reports no personal financial relationships with industry in the 36 months prior to publication. He serves as principal investigator of the SCREEN-AF trial (uncompensated; trial funded by the Canadian Stroke Prevention Intervention Network (C-SPIN), which is funded by the Canadian Institutes of Health Research [CIHR]), and as a national co–principal investigator for the Canadian arm of the ARCADIA trial, which is funded by the National Institutes of Health. Dr. Gladstone previously served as an independent medical safety monitor for that trial (uncompensated); principal investigator of a research grant from the CIHR-funded C-SPIN Network for the Ontario Holter/Echo Database; and a local site investigator for NAVIGATE ESUS, and NASPAF-ICH (all site fees paid to institution). Alexandre Poppe is site principal investigator and site co-investigator for NoNo and Bayer and has received a grant from Canadian Stroke Trials for Optimized Results. Alan Bell reports receving personal fees from AstraZeneca Novartis, Pfizer, Servier and Bayer, outside the submitted work. He is the vice-president of Thrombosis Canada (unpaid position), serves on the board of directors of Hypertension Canada (unpaid position) and was an author of the Antiplatelet Guideline of the Canadian Cardiovascular Society. Leanne K Casaubon reports receiving personal fees from Medtronic and Bayer and is site principal investigator for a clinical trial related to NA1 by NoNo Inc. (no personal financial compensation). James Douketis reports receiving personal fees from Leo Pharma, Janssen, Pfizer, Bristol-Myers Squibb, Sanofi, Servier Canada and Portola, which are deposited in hospital-based (St. Joseph’s Healthcare Hamilton) and university-based (McMaster University) research accounts or charitable foundations. Dr. Douketis also reports receiving personal fees as an employee of The Merck Manual and UpTo-Date. Thalia Field reports receiving grants and personal fees from Bayer Canada, and personal fees from Pfizer-BMS and Servier, outside the submitted work. Jeffrey Habert reports receiving personal fees from Pfizer, Amgen, BMS, Bayer, Boehringer Ingelheim, Eli-Lilly, Purdue, Allergan, AstraZeneca, Lundbeck, Novo-Nordisk, Servier, Janssen, Roche, HLS,
Funding Information:
Otsuka (speaker, advisory board or consulting), and from Alliance, MD-Briefcase, Bausch, Liv, MedPlan, Brandaide, Academy, Bridge, Seacourses, Meducom, the International Centre for Professional Development in Health and Medicine, CPD Network, Antibody, CHRC, STA Healthcare Communications, CTC, Canadian Collaborative Research Network, Four Health Comm (scientific committee, consulting), outside the submitted work. Shamir Mehta reports receiving grants and personal fees from AstraZeneca, grants from Boston Scientific, and personal fees from Bayer. William Semchuk reports receiving personal fees from Bayer, Pfizer, Servier, BMS, Sanofi, and AstraZeneca, outside the submitted work. Mikul Sharma reports receiving grants and honoraria from Bayer, grants from Boehringer Ingelheim and Bristol-Myers Squibb, and consulting fees from Portola and Daiichi Sankyo. Jacob Udell reports receiving grants and personal fees from AstraZeneca, Boehringer Ingel-heim, Janssen and Sanofi. Eric E Smith has received personal fees from Portola Pharmaceuticals and Biogen. Dar Dowlatshahi has received a grant from the Heart and Stroke Foundation of Canada and honoraria from Bayer, BMS and Apopharma, outside the submitted work. Gord Gubitz is a member of advisory boards for Bayer, Boehringer Ingelheim and Pfizer. No other competing interests were declared.
Funding Information:
Funding: The development of the Canadian Stroke Best Practice Recommendations is funded in its entirety by the Heart and Stroke Foundation of Canada. No funds for the development of these guidelines are received from commercial interests, including pharmaceutical and medical device companies. Members of the recommendation writing groups and external reviewers are volunteers and do not receive any remuneration for participation in guideline development, updates and reviews.
ASJC Scopus Subject Areas
- General Medicine
PubMed: MeSH publication types
- Journal Article
- Practice Guideline